Corredor Jeisson D, Febres-Molina Camilo, Jaña Gonzalo A, Jiménez Verónica A
Doctorado en Fisicoquímica Molecular, Facultad de Ciencias Exactas, Universidad Andres Bello, República 275, Santiago 8370146, Chile.
Departamento de Ciencias Químicas, Facultad de Ciencias Exactas, Universidad Andres Bello, Autopista Concepción-Talcahuano 7100, Talcahuano 4260000, Chile.
J Chem Inf Model. 2023 Feb 27;63(4):1338-1350. doi: 10.1021/acs.jcim.2c01558. Epub 2023 Feb 9.
Vildagliptin (VIL) is an antidiabetic drug that inhibits dipeptidyl peptidase-4 (DPP4) through a covalent mechanism. The molecular bases for this inhibitory process have been addressed experimentally and computationally. Nevertheless, relevant issues remain unknown such as the roles of active site protonation states and conserved water molecules nearby the catalytic center. In this work, molecular dynamics simulations were applied to examine the structures of 12 noncovalent VIL-DPP4 complexes encompassing all possible protonation states of three noncatalytic residues (His126, Asp663, Asp709) that were inconclusively predicted by different computational tools. A catalytically competent complex structure was only achieved in the system with His126 in its ε-form and nonconventional neutral states for Asp663/Asp709. This complex suggested the involvement of one water molecule in the catalytic process of His740/Ser630 activation, which was confirmed by QM/MM simulations. Our findings support the suitability of a novel water-mediated mechanism in which His740/Ser630 activation occurs concertedly with the nucleophilic attack on VIL and the imidate protonation by Tyr547. Then, the restoration of His740/ Tyr547 protonation states occurs via a two-water hydrogen bonding network in a low-barrier process, thus describing the final step of the catalytic cycle for the first time. Additionally, two hydrolytic mechanisms were proposed based on the hydrogen bonding networks formed by water molecules and the catalytic residues along the inhibitory mechanism. These findings are valuable to unveil the molecular features of the covalent inhibition of DPP4 by VIL and support the future development of novel derivatives with improved structural or mechanistic profiles.
维格列汀(VIL)是一种抗糖尿病药物,它通过共价机制抑制二肽基肽酶-4(DPP4)。这一抑制过程的分子基础已通过实验和计算方法进行了研究。然而,一些相关问题仍然未知,例如活性部位质子化状态以及催化中心附近保守水分子的作用。在这项工作中,我们应用分子动力学模拟来研究12种非共价VIL-DPP4复合物的结构,这些复合物涵盖了三个非催化残基(His126、Asp663、Asp709)的所有可能质子化状态,不同的计算工具对这些状态的预测并不确定。只有在His126处于其ε形式且Asp663/Asp709处于非常规中性状态的系统中,才获得了具有催化活性的复合物结构。该复合物表明一个水分子参与了His740/Ser630激活的催化过程,这一点通过量子力学/分子力学(QM/MM)模拟得到了证实。我们的研究结果支持了一种新的水介导机制的适用性,即His740/Ser630的激活与对VIL的亲核攻击以及Tyr547对亚胺酯的质子化协同发生。然后,His740/Tyr547质子化状态通过一个低势垒过程中的双水氢键网络得以恢复,从而首次描述了催化循环的最后一步。此外,基于水分子与抑制机制中催化残基形成的氢键网络,提出了两种水解机制。这些发现对于揭示VIL对DPP4共价抑制的分子特征具有重要价值,并为未来开发具有改进结构或机制特征的新型衍生物提供了支持。